Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 11/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791798 | 0.88 | PKM (0.64) | TDO2PKMAKR1C3AKR1C1CXCR4 | |
| SCHEMBL7436813 | 0.81 | AKR1C3 (0.50) | PKMF10AKR1C3AKR1C1 | |
| SCHEMBL2266915 | 0.80 | PKM (0.73) | PKMF10GLA | |
| Hydrochloric Acid SCHEMBL5733824 | 0.79 | PKM (0.71) | PKMF10GLA | |
| SCHEMBL6789523 | 0.78 | KMT2A (0.48) | PKM | |
| SCHEMBL25059352 | 0.77 | TDO2 (0.56) | TDO2CXCR4 | |
| SCHEMBL5633406 | 0.73 | PKM (0.62) | PKMF10GLA | |
| Hydrochloric Acid SCHEMBL6734214 | 0.73 | F10 (0.48) | PKMF10AKR1C3AKR1C1CXCR4 | |
| SCHEMBL6301308 | 0.72 | PKM (0.45) | PKMF10 | |
| Hydrochloric Acid SCHEMBL5633273 | 0.72 | PKM (0.60) | PKMF10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| EP-0937048-B1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ASTRAZENECA AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| EP-1358909-A1 | Heteroaryl-phenyl derivatives as factor xa inhibitors for use as antithrombotic and anticoagulant agents | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195203-A1 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195203-A1 | Heterocyclic derivatives | F12, F11, F2 | TDO2 1975/4885PKM 3921/4885F10 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.